Visceral abdominal fat is the #1 body composition complaint during menopause and perimenopause. Declining estrogen triggers fat redistribution from hips and thighs to the midsection, and it's stubbornly resistant to diet and exercise alone. Tesamorelin and AOD-9604 both target fat metabolism, but one has FDA approval and the other remains a research peptide. Here's what the evidence says for women.
| Tesamorelin | AOD-9604 | |
|---|---|---|
| FDA status | FDA approved (lipodystrophy) | Not FDA approved — Category 1 research |
| Mechanism | Growth hormone releasing hormone (GHRH) analog — stimulates pituitary GH release | Modified fragment of hGH (amino acids 177–191) — direct lipolysis |
| Primary target | Visceral abdominal fat (VAT) | General fat metabolism — less visceral-specific |
| GH elevation | Yes — raises IGF-1 significantly | No — does not raise GH or IGF-1 |
| Administration | Subcutaneous injection (daily) | Subcutaneous injection (daily) |
| Evidence level | ★★★★ — Phase 3 RCTs | ★★★ — Phase 2 data + preclinical |
| Key trial result | Reduced trunk fat by 14% in 26 weeks (Falutz 2007) | Reduced body fat in obese subjects over 12 weeks (Heffernan 2001) |
| Side effects | Injection site reactions, joint pain, fluid retention | Generally well-tolerated; minimal reported side effects |
Why Menopause Changes Where Fat Goes
Before menopause, estrogen directs fat storage toward subcutaneous depots in the hips, thighs, and breasts. As estrogen declines, this protective distribution pattern breaks down. Fat migrates to the visceral compartment — the deep abdominal fat surrounding organs that drives insulin resistance, cardiovascular risk, and systemic inflammation.
This isn't about willpower. It's a hormonal redistribution that occurs independently of caloric intake, and it's why many women in their late 40s and 50s report gaining abdominal fat despite maintaining the same diet and exercise habits that kept them lean for decades.
Tesamorelin — The FDA-Approved Option
Tesamorelin (brand name Egrifta) is a synthetic GHRH analog that stimulates the pituitary gland to release growth hormone in a physiological pulsatile pattern. It holds FDA approval for reducing excess abdominal fat in HIV-associated lipodystrophy — making it the only growth hormone peptide with FDA approval.
The Phase 3 trial demonstrated a 14% reduction in trunk fat over 26 weeks. Importantly, Tesamorelin specifically targets visceral adipose tissue (VAT) rather than subcutaneous fat, which makes it particularly relevant for menopause-related central adiposity.
Because Tesamorelin raises GH and IGF-1, it also provides secondary benefits: improved sleep quality, better skin elasticity, and support for lean body mass — all of which decline during menopause.
Falutz J, et al. N Engl J Med. 2007;357(23):2359-2370. PMID: 18057338AOD-9604 — The GH Fragment
AOD-9604 is a modified fragment of human growth hormone (amino acids 177–191). It was designed to isolate the fat-metabolizing region of GH without triggering the growth-promoting effects. The key advantage: AOD-9604 does not raise IGF-1 or cause the side effects associated with full GH elevation.
Phase 2 data showed statistically significant fat loss in obese subjects. However, the evidence base is thinner than Tesamorelin's, and the peptide has not progressed through Phase 3 trials or achieved FDA approval.
For women concerned about GH-related side effects (joint pain, fluid retention, potential impact on breast tissue), AOD-9604's GH-independent mechanism is a meaningful differentiator.
Heffernan M, et al. Obes Res. 2001;9(Suppl 3):187S. (Conference abstract)Which Is Better for Menopause Belly Fat?
If your primary concern is visceral abdominal fat (the deep belly fat that drives metabolic risk), Tesamorelin has stronger evidence. Its Phase 3 data specifically demonstrated visceral fat reduction, and the GH-mediated mechanism directly addresses the hormonal driver of menopause-related fat redistribution.
If you want fat loss support without raising growth hormone levels — perhaps because you're already on a GH secretagogue like CJC-1295/Ipamorelin, or you're concerned about IGF-1 elevation — AOD-9604 provides a cleaner, more targeted approach.
Some practitioners stack both for complementary coverage: Tesamorelin for visceral-specific reduction plus AOD-9604 for broader fat metabolism support.
The Verdict for Women
Choose Tesamorelin if visceral belly fat is your primary target and you want the strongest evidence base — it's the only FDA-approved GH peptide and specifically reduces trunk fat. Choose AOD-9604 if you want fat metabolism support without GH/IGF-1 elevation, or if you're already using another GH secretagogue. For menopause-specific body composition, Tesamorelin is the stronger first-line choice.